NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $414,339 | +16.1% | 11,548 | +27.7% | 0.00% | – |
| Q4 2022 | $356,766 | -20.9% | 9,041 | -2.3% | 0.00% | -100.0% |
| Q3 2022 | $451,000 | +79.0% | 9,254 | +166.6% | 0.00% | – |
| Q1 2022 | $252,000 | -38.7% | 3,471 | +18.7% | 0.00% | – |
| Q1 2021 | $411,000 | +59.3% | 2,923 | +95.4% | 0.00% | – |
| Q4 2020 | $258,000 | -89.7% | 1,496 | -92.9% | 0.00% | -100.0% |
| Q2 2020 | $2,516,000 | +597.0% | 21,062 | +577.5% | 0.01% | +400.0% |
| Q4 2019 | $361,000 | +31.8% | 3,109 | -2.4% | 0.00% | 0.0% |
| Q3 2019 | $274,000 | -90.8% | 3,187 | -93.0% | 0.00% | -83.3% |
| Q2 2019 | $2,972,000 | +76.9% | 45,850 | +162.0% | 0.01% | +50.0% |
| Q1 2017 | $1,680,000 | +340.9% | 17,503 | +234.2% | 0.00% | +300.0% |
| Q4 2016 | $381,000 | – | 5,238 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |